A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Amatuximab (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Sponsors Morphotek
- 02 Feb 2017 Planned End Date changed from 1 Sep 2020 to 1 Sep 2018.
- 02 Feb 2017 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2017.
- 02 Feb 2017 Status changed from recruiting to active, no longer recruiting.